Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.

MLA

Gupta, Samir K., et al. “Efficacy, Safety, Bone and Metabolic Effects of HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): A Phase 2b Randomised, Controlled, Partly Blinded Trial.” The Lancet. HIV, vol. 3, no. 1, Jan. 2016, pp. e13–22. EBSCOhost, https://doi.org/10.1016/S2352-3018(15)00231-3.

APA

Gupta, S. K., McComsey, G. A., Lombaard, J., Echevarría, J., Orrell, C., Avihingsanon, A., Osiyemi, O., Santoscoy, M., Ray, N., Stock, D. A., Joshi, S. R., Hanna, G. J., & Lataillade, M. (2016). Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. The Lancet. HIV, 3(1), e13–e22. https://doi.org/10.1016/S2352-3018(15)00231-3

Chicago

Gupta, Samir K, Grace A McComsey, John Lombaard, Juan Echevarría, Catherine Orrell, Anchalee Avihingsanon, Olayemi Osiyemi, et al. 2016. “Efficacy, Safety, Bone and Metabolic Effects of HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): A Phase 2b Randomised, Controlled, Partly Blinded Trial.” The Lancet. HIV 3 (1): e13–22. doi:10.1016/S2352-3018(15)00231-3.